Group 1 - The Hong Kong stock market opened higher on September 29, with the Hang Seng Index at 26,321 points, up 193 points, a 0.74% increase, and the Hang Seng Tech Index at 6,236 points, up 41 points, a 0.67% increase [1] - Lai Kai Pharmaceutical-B (02105.HK) saw a surge of over 30% after announcing positive preliminary results from its LAE102 Phase I multi-dose escalation study for obesity, which included overweight/obese participants with an average BMI of 29.4 kg/m² [3] - In the LAE102 study, the 6 mg/kg dose group showed an average lean body mass increase of 1.7% and a fat mass reduction of 2.2% by week 5, with adjusted averages showing a 4.6% increase in lean body mass and a 3.6% reduction in fat mass compared to the placebo group [3] - The study results align with previous Phase I single-dose escalation study findings, demonstrating good tolerability and safety, with no serious adverse events reported [3] - Lai Kai Pharmaceutical is actively negotiating with potential partners to accelerate the clinical development and commercialization of LAE102 [3] Group 2 - The market outlook suggests increased volatility, but the long-term upward trend remains intact, with AI being a key focus for the Hong Kong stock market [6] - The metals sector is expected to benefit from liquidity easing due to interest rate cuts and rising inflation expectations [6] - Recommendations include focusing on technology (including AI internet and high-end manufacturing) and metals as market mainstays, while also considering undervalued insurance stocks and high-dividend value strategies [6] - Some undervalued innovative pharmaceutical stocks may be suitable for bottom-up investment [6]
港股早盘高开 来凯医药短线涨超30%